Grantham, Mayo, Van Otterloo & Co (GMO)’s Verona Pharma VRNA Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-264,115	Closed	-$28.2M	–	710
2025 Q3	$28.2M	Buy	+264,115	New	+$27.6M	0.08%	133

Other funds holding VRNA

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s VRNA Position: Q4 2025 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 264,115 shares — an estimated $28.2M sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in VRNA in Q3 2025 and held it in 1 quarter. The position peaked at $28.2M in Q3 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
Grantham, Mayo, Van Otterloo & Co (GMO) sold 264,115 Verona Pharma shares in Q4 2025, an estimated $28.2M.
Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Verona Pharma in Q3 2025 and held it in 1 quarter.
Grantham, Mayo, Van Otterloo & Co (GMO)'s Verona Pharma position peaked at $28.2M in Q3 2025.
1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q4 2025, filed 17 Feb 2026.